Previous 10 | Next 10 |
home / stock / nrx:cc / nrx:cc news
TORONTO and HAIFA, Israel, Feb. 20, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company, proudly underscores its expanding Intellectual Property (IP) portfolio, which will serv...
TORONTO and HAIFA, Israel, Feb. 14, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”), a biopharmaceutical company, announced today the commencement of efforts to license its proprietary ExoTherapy platform for cre...
TORONTO and HAIFA, Israel, Feb. 02, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V), known as "NurExone," is pleased to announce the initiation of the Orphan Drug Designation process with the European Medicines Agency (EMA) for its groundbreaking ExoPTEN product, cu...
(NewsDirect) Investors eyeing dynamic opportunities in healthcare should take note of the burgeoning growth anticipated in the spinal cord injury market. Projections for robust advancements, driven by enhanced diagnosis and increased global healthcare spending, signal a lucrative trajectory f...
TORONTO and HAIFA, Israel, Jan. 17, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “ Company ” or “ NurExone ”), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal c...
TORONTO and HAIFA, Israel , Jan. 05, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “ Company ” or “ NurExone ”), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal ...
TORONTO and HAIFA, Israel, Nov. 29, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “Company” or “NurExone”) has recently unveiled laboratory tests of its secondary two proprietary sequences, representing a significant advancement in...
TORONTO and HAIFA, Israel, Nov. 24, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “Company” or “NurExone”), a pioneering biotechnology company, released a corporate update and reported financial results for the quarter ended Septem...
Green Impact Partners Inc. (GIP:CA) is expected to report $-0.06 for Q3 2023 Valdor Technology International Inc. (VTI:CA) is expected to report for Q1 2024 Lycos Energy Inc. (LCX:CA) is expected to report for Q1 2024 49 North Resources Inc. (FNR:CA) is expected to report for quarter ...
NurExone Biologic Inc. (NRX:CA) is expected to report $-0.03 for Q3 2023
News, Short Squeeze, Breakout and More Instantly...
NurExone Biologic Inc. Company Name:
NRX:CC Stock Symbol:
TSXVC Market:
NurExone Biologic Inc. Website:
TORONTO and HAIFA, Israel, July 17, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company, is pleased to announce the preliminary results from a small-scale cont...
TORONTO and HAIFA, Israel, July 05, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “ Company ” or “ NurExone ”), a pioneering biopharmaceutical company, is pleased to announce two significant updates aimed at ad...
TORONTO and HAIFA, Israel, June 28, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “ Company ” or “ NurExone ”), a pioneering biopharmaceutical company, is pleased to announce a pre-clinical study to explore the...